Journals / ENT Updates / 2018 / Cilt: 8 - Sayı: 1

Predictive and prognostic values of pretreatment functional imaging-based biomarkers in advanced-stage laryngeal cancer

‹leri evre larenks kanserinde tedavi öncesi fonksiyonel görüntülemeye dayal› biyobelirteçlerin öngördürücü ve prognostik de¤eri

Pages
1–12
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results demonstrated that pretreatment SUV and MTImean values were predictive factors for staging, N-stage and PNI.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine the quantitative values of apparent diffusion coefficient (ADC), standardized uptake values(SUVmax, SUVmean), metabolic tumor volume (MTV), metabolic tumor volume indexes (MTImax, and MTImean) using diffusion weighted-MRI (DW-MRI) and positron emission tomography/computed tomography (PET/CT), and analyze the predictive and prognostic values of these biomarkers in a homogenous group of patients with advanced-stage laryngeal cancer.
📊
Key Findings & Data:Methods: Patients with newly diagnosed advanced-stage laryngeal cancer who had both DW-MRI and 18F-FDG PET/CT before treatment, and who had curative cancer treatment (surgery ± adjuvant therapy or radio ± chemotherapy) between 2011 and 2015 were included in this study.
💡
Conclusion & Impact:Conclusion: Our results demonstrated that pretreatment SUV and MTImean values were predictive factors for staging, N-stage and PNI.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To determine the quantitative values of apparent diffusion coefficient (ADC), standardized uptake values(SUVmax, SUVmean), metabolic tumor volume (MTV), metabolic tumor volume indexes (MTImax, and MTImean) using diffusion weighted-MRI (DW-MRI) and positron emission tomography/computed tomography (PET/CT), and analyze the predictive and prognostic values of these biomarkers in a homogenous group of patients with advanced-stage laryngeal cancer. Methods: Patients with newly diagnosed advanced-stage laryngeal cancer who had both DW-MRI and 18F-FDG PET/CT before treatment, and who had curative cancer treatment (surgery ± adjuvant therapy or radio ± chemotherapy) between 2011 and 2015 were included in this study. All patients were followed up clinically and radiologically, if necessary every 3 months for the first 2 years, every 4–6 months for year 3, and then annually thereafter. Results: Thirty-eight patients were retrospectively analyzed. Our analysis demonstrated statistically significant differences when the pretreatment SUV and MTImean value were compared between patients with stages III and IV. Standardized uptake value was also a predictive factor for N-stage. Moreover, a statistically significant difference was determined when patients with and without perinodal involvement (PNI) were compared. Log rank analysis demonstrated that none of functional imaging-based biomarkers had a prognostic role for oncological outcomes. Conclusion: Our results demonstrated that pretreatment SUV and MTImean values were predictive factors for staging, N-stage and PNI. Indeed, functional imaging-based biomarkers are promising, novel, noninvasive techniques that may provide additional information about tumor characteristics, treatment selection and prognosis in the near future.

Özet

Amaç: Difüzyon a¤›rl›kl› MR görüntüleme (DW-MRI) ve pozitron emisyon tomografi/bilgisayarl› tomografiyi (PET/BT) kullanarak görünür difüzyon katsay›s›n›n (ADC) nicel de¤erleri, standardize edilmifl tutulum de¤eri (SUVmaks, SUVort), metabolik tümör volümü (MTV), metabolik tümör volüm göstergelerini (MTImaks ve MTIort)belirlemek ve ileri evre larenks kanserli homojen hasta grubunda bu biyobelirteçlerin öngördürücü ve prognostik de¤erlerini incelemektir. Yöntem: Yeni tan› konmufl ileri evre larenks kanserli, tedavi öncesi hem DW-MRI hem de 18F-FDG PET/BT çektirmifl ve 2011–2015 y›llar› aras›nda küratif kanser tedavisi görmüfl (cerrahi ± adjuvan tedavi veya radyoterapi ± kemoterapi) hastalar çal›flmaya dahil edildi. Hastalar›n tümü gerekti¤inde ilk 2 y›l 3 ayda bir, 3. y›l 4–6 ayda bir ve daha sonra y›lda bir klinik ve radyolojik olarak izlendi. Bulgular: Otuz sekiz hasta geriye dönük olarak incelendi. ‹ncelememiz evre III ve IV hastalar aras›nda tedavi öncesi SUV ve MTIort de¤erleri aç›s›ndan istatistiksel aç›dan anlaml› farkl›l›klar oldu¤unu gösterdi. Standardize edilmifl tutulum de¤eri evresi de N-evresi için bir öngördürücü faktördü. Ayr›ca perinodal tutulumu (PNT) olan ve olmayan hastalar aras›nda da istatistiksel aç›dan anlaml› farkl›l›k olduğu belirlendi. Logaritmik s›ralama çözümlemesi, fonksiyonel görüntülemeye dayal› biyobelirteçlerin hiçbirisinin onkolojik sonuçlar aç›s›ndan prognostik role sahip olmad›¤›n› gösterdi. Sonuç: Bulgular›m›z tedavi öncesi SUV ve MTIort de¤erlerinin evreleme, N-evresi ve PNT aç›s›ndan öngördürücü faktörler oldu¤unu göstermifltir. Gerçekten de fonksiyonel görüntülemeye dayal› biyobelirteçler tümörün özellikleri, tedavi seçimi ve yak›n dönem prognozu hakk›nda ek bilgi sa¤layan umut verici, yeni ve giriflimsel olmayan tekniklerdir.

🔖

Cite This Article

ESKİİZMİR, G., ÖZYURT, B. C., OVALI, G. Y., TARHAN, S., ARAS, F. (2022). Predictive and prognostic values of pretreatment functional imaging-based biomarkers in advanced-stage laryngeal cancer. ENT Updates, Cilt: 8 - Sayı: 1, 1–12. https://ajindex.com/articles/501412

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Rudolph E, Dyckhoff G, Becher H, Dietz A, Ramroth H. Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis. Eur Arch Otorhinolaryngol 2011;268:165–79.
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7–30.
  3. Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin 2017;67:31–50.
  4. Bussu F, Micciche F, Rigante M, et al. Oncologic outcomes in advanced laryngeal squamous cell carcinomas treated with differ- ent modalities in a single institution: a retrospective analysis of 65 cases. Head Neck 2012;34:573–9.
  5. Salvador-Coloma C, Cohen E. Multidisciplinary care of laryngeal cancer. J Oncol Pract 2016;12:717–24.
  6. Eskiizmir G, Bask›n Y, Yalç›n F, Ellidokuz H, Ferris RL. Risk fac- tors for radiation failure in early-stage glottic carcinoma: a system- atic review and meta-analysis. Oral Oncol 2016;62:90–100.
  7. Eskiizmir G, Tanyeri Toker G, Celik O, Gunhan K, Tan A, Ellidokuz H. Predictive and prognostic factors for patients with locoregionally advanced laryngeal carcinoma treated with surgical multimodality protocol. Eur Arch Otorhinolaryngol 2017;274: 1701–11. Abraham J. Imaging for head and neck cancer. Surg Oncol Clin N Am 2015;24:455–71.
  8. Maroldi R, Ravanelli M, Farina D. Magnetic resonance for laryn- geal cancer. Curr Opin Otolaryngol Head Neck Surg 2014;22: 131–9.
  9. Suenaga Y, Kitajima K, Kanda T, et al. [(18)F]-FDG PET/CT imaging for detection of nodal metastases in patients with squa- mous cell carcinoma of the pharynx and larynx: comparison with CT. Jpn J Radiol 2016;34:203–10.
  10. Mehanna H, Wong HL, McConkey CC, et al.; PET-NECK Trial Management Group. PET-CT surveillance versus neck dissectionin advanced head and neck cancer. N Engl J Med 2016;374:1444– 54. Mehanna H, McConkey CC, Rahman JK, et al. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guid- ed watch-and-wait policy with planned neck dissection in the man- agement of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 2017;21:1–122.
  11. Cammaroto G, Quartuccio N, Sindoni A, Di Mauro F, Caobelli F; Young AIMN Working Group. The role of PET/CT in the man- agement of patients affected by head and neck tumors: a review of the literature. Eur Arch Otorhinolaryngol 2016;273:1961–73.
  12. Shang DS, Ruan LX, Zhou SH, Bao YY, Cheng